CalbaTech, which recently acquired oligo and reagent provider Molecula Research Laboratories, said this week that it has appointed Paul Heaney to its scientific advisory board.
Heaney received a PhD in medicinal chemistry from the University of Glasgow, said CalbaTech, and has held senior research and development positions at Amersham International (now Amersham Biosciences), Kodak Clinical Diagnostics (now Ortho-Clinical Diagnostics), Genometrix, Orchid Biosciences, and Sequenom.
Heaney joins former Smith Kline Beecham executive David O’Bryan and Nobel Laureate Kary Mullis on CalbaTech’s scien- tific advisory board, the company added.
CytoGenix announced this week that it has named Samuel Kaplan to its scientific advisory board.
Kaplan is professor and chairman of the department of molecular bio- logy at the University of Texas Houston Medical School and chairman of the publication board of the American Society of Microbiology, said the company. He holds a bachelor’s degree from Cornell University, a masters from Yale, and a PhD in molecular genetics from UC San Diego.